Charles River Laboratories Intl. Inc (NYSE:CRL) insider David Ross Smith sold 5,486 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $109.53, for a total value of $600,881.58. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Charles River Laboratories Intl. Inc (CRL) traded down $0.34 during trading on Wednesday, reaching $110.31. The company’s stock had a trading volume of 404,993 shares, compared to its average volume of 376,250. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62. The firm has a market capitalization of $5,210.00, a price-to-earnings ratio of 26.97, a price-to-earnings-growth ratio of 1.61 and a beta of 0.88. Charles River Laboratories Intl. Inc has a 12 month low of $77.31 and a 12 month high of $119.05.

Charles River Laboratories Intl. (NYSE:CRL) last posted its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.08. The company had revenue of $464.23 million for the quarter, compared to analyst estimates of $458.93 million. Charles River Laboratories Intl. had a return on equity of 26.58% and a net margin of 10.72%. Charles River Laboratories Intl.’s revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 earnings per share. equities research analysts anticipate that Charles River Laboratories Intl. Inc will post 5.14 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. YorkBridge Wealth Partners LLC grew its holdings in Charles River Laboratories Intl. by 445.5% in the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after purchasing an additional 891 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of Charles River Laboratories Intl. by 69.0% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after acquiring an additional 548 shares in the last quarter. Advisor Group Inc. lifted its position in shares of Charles River Laboratories Intl. by 159.4% in the third quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock valued at $165,000 after acquiring an additional 945 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Charles River Laboratories Intl. by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after acquiring an additional 202 shares in the last quarter. Finally, Riverhead Capital Management LLC lifted its position in shares of Charles River Laboratories Intl. by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after acquiring an additional 247 shares in the last quarter. 95.80% of the stock is currently owned by institutional investors.

A number of research analysts recently weighed in on CRL shares. Bank of America dropped their price objective on Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, November 10th. Zacks Investment Research raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 price objective on the stock in a report on Tuesday, October 24th. Argus started coverage on Charles River Laboratories Intl. in a report on Wednesday, December 13th. They set a “buy” rating and a $120.00 price objective on the stock. ValuEngine lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Finally, Royal Bank of Canada began coverage on Charles River Laboratories Intl. in a report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Charles River Laboratories Intl. presently has an average rating of “Buy” and an average target price of $110.21.

ILLEGAL ACTIVITY WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/03/insider-selling-charles-river-laboratories-intl-inc-crl-insider-sells-5486-shares-of-stock.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.